Company: GMRE
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001104659-25-110926
Chunk: 14

Company: Global Medical REIT Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 14
---
 gross sales price of up to $300.0 million, including through forward sales. See “Use                                                                                                  
 of Proceeds” and “Underwriting—Conflicts of Interest and Other Relationships.”                                                                                                                                                       |
| Transfer                            
 Agent, Registrar and Depositary     | Equiniti Trust Company, LLC                                                                                                                                                                                                          
 will be the transfer agent, registrar, dividend disbursing agent, redemption agent and depositary for the Series B Preferred                                                                                                         
 Stock.                                                                                                                                                                                                                               |
| Risk Factors                        | Investing in our Series B                                                                                                                                                                                                            
 Preferred Stock involves various risks. You should read carefully and consider the risks discussed under the caption “Risk                                                                                                           
 Factors” beginning on page S-8 of this prospectus supplement and the “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and incorporated by reference herein, before making a decision to invest 
 in our Series B Preferred Stock.                                                                                                                                                                                                     |

| Settlement | The underwriters expect to deliver the shares of Series B Preferred Stock against payment therefor through DTC on or about                , 2025, which is the           business day 
 following the pricing of this offering.                                                                                                                                               |

<div align='center'>S-7

RISK FACTORS</div>

Before purchasing any securities offered by this prospectus supplement, you should carefully consider the risk factors incorporated by reference into this prospectus supplement from our A nnual Report on Form 10-K for the year ended December 31, 2024, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as well as the other risks, uncertainties and additional information set forth in our SEC reports on Form 10-K, Form 10-Q and Form 8-K and in the other documents incorporated by reference into this prospectus supplement, and the accompanying prospectus. For a description of these reports and documents, and information about where you can find them, see “Where You Can Find More Information” and “Incorporation by Reference of Information Filed with the SEC.” Some statements in this prospectus supplement, including statements contained in the following risk factors, constitute forward-looking statements. Please see “Cautionary Note Regarding Forward-Looking Statements.”

Risks Related to This Offering and Our Business

Our Series B Preferred Stock has not been rated by a nationally recognized statistical rating organization.

We have not sought to obtain a rating for our
Series B Preferred Stock from a nationally recognized statistical rating organization. However